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RAS polymorphismAbstract Background: Genetic variability in the genes of different components of renin-angioten-
sin system (RAS) is likely to contribute for its heterogenous association in renal diseased patients.
Among the candidate genes of RAS, angiotensin II type 1 receptor gene polymorphism (AT1R
A1166C) seems to be particularly biologically and clinically relevant to renal diseases.
The aim: This study was to evaluate the association of AT1R A1166C gene polymorphism in adult
Egyptian hemodialysis (HD) patients. Its association with hypertension was also done.
Subjects and methods: The study was conducted on 202 adult Egyptian subjects: 100 controls and
102 HD patients. Determination of this polymorphism was done by PCR/RFLP strategy.
Results: It revealed that HD patients had signiﬁcantly higher frequency in AC and CC genotypes
than controls. But on dividing these patients to normotensive and hypertensive ones, no signiﬁcant
difference in the genotypes was found. The multiple regression analysis revealed no dependent vari-
ables on the AT1R A1166C gene polymorphism.
Conclusion: This study suggested that CC/AC genotype could serve as a predictor of an early end-
stage renal disease (ESRD) and could, in the future, become an important part of the clinical pro-
cess of renal risk identiﬁcation.
ª 2014 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Renal function and blood pressure are tightly linked. Physio-
logically, kidneys provide a key regulator of both blood pres-sure and body ﬂuids, via renin-angiotensin–aldosterone system
(RAAS).1 This enzymatic cascade acts as an endocrine and
paracrine system that results in the production of angiotensin
II (AngII). 2,3 Angiotensin II type 1 receptor (AT1R) mediates
most of the action of AngII and therefore modulates the
RAAS.4,5 The role of RAAS in the pathogenesis of hyper-
tension is well documented, but its contribution to chronic
renal failure (CRF) is still debated.6–8
Hypertension is a major contributor in the progression
of renal disease to renal failure.7,9 It affects up to 90% of
340 H. El-banawy et al.hemodialysis patients and is a risk factor for adverse cardiovas-
cular outcomes.10,11
The impact of genetic variability on the development of
renal failure emphasizes the need to elucidate its genetic
basis.12 Genetic polymorphism of RAAS has been associated
with organ damage in essential hypertension.13 A great num-
ber of AT1R gene polymorphisms have been identiﬁed and
the most studied one is the A1166C variant.2–5,8,10–14 It is a
polymorphism in the 03 untranslated region of the gene encod-
ing human AT1R, corresponding to adenine (A) to cytosine
(C) transversion at position 1166 (rs 5186).15
The AT1R A1166C gene polymorphism was reported to be
implicated as a risk factor for hypertension.15–19 However, pre-
vious studies showed conﬂicting data concerning the associa-
tion of AT1R C 1166 allele with the progression of renal
dysfunction and its inﬂuence on the patient’s susceptibility to
CRF or end-stage renal disease (ESRD).4,5,12,15,20–23
To our knowledge the inﬂuence of AT1R A1166C gene
polymorphism on the development of ESRD in adult Egyptian
patients, especially those with hypertension has not yet
reported. There was only one report on the association of this
polymorphism in Egyptian hemodialysis children.12 Therefore,
the present study was designed to determine whether the AT1
R A1166 C gene polymorphism, if present, is involved in the
occurrence of ESRD in adult Egyptian hemodialysis patients;
its relation to the presence of hypertension was also studied.
2. Subjects
After the approval of the Ethical Committee of the Medical
Research Institute (MRI), this case control study was con-
ducted on 102 adult Egyptian hemodialysis (HD) patients
(50 males & 52 females) with a mean age of 50.5 ± 14.0 years.
They were recruited from the Nephrology Unit of the MRI
teaching hospital, Alexandria University. One 100 adult
healthy volunteers (35 males & 65 females) with a mean age
of 56.0 ± 10.2 years were also included. They had no family
history of hypertension. Written informed consents were taken
from all subjects included in this study, which was done from
April to December 2013.
Etiology of ESRD was diabetic nephropathy (28 cases),
hypertension (24 cases), primary glomerulonephritis (16 cases),
obstructive uropathy (10 cases), lupus nephritis (8 cases), drug
induced nephropathy (4 cases), eclampsia (3 cases), adult poly-
cystic kidney disease (2 cases), congenital anomalies (2 cases),
acute tubular necrosis (one case) and unknown etiology (4
cases).
The patients were under maintenance HD for more than
one year (the median duration of HD was ﬁve years), as four
hours thrice weekly, using polysulphone hollow ﬁber dialyzers
and bicarbonate-buffered dialysate.
N.B.: Patients with malignancy, pulmonary hypertension,
liver cirrhosis, ascites, heart failure, atrial ﬁbrillation, or ische-
mic heart disease were excluded.
The HD patients were further subdivided according to the
presence of hypertension (Ht) into: normotensive group (30
patients) and hypertensive group (72 patients) (their median
duration of Ht was 10 years). The hypertensive group was
further subdivided according to the type of antihypertensive
therapy into: those taking RAS suppressors either angiotensin-
converting enzyme inhibitors (ACEIs) or angiotensin II type1 receptor blockers (ARBs)], either alone or in combination
with others (34 patients). The other subgroup was those using
RAS suppressors [e.g. b-blockers, calcium channel blockers
and /or diuretics] (38 patients).
3. Methods
To all subjects, full clinical examination was done, with special
stress in patients on age, duration of dialysis and detailed his-
tory of hypertension, diabetes and therapy. Predialysis mea-
surement of blood pressure (BP) for three times was done
after resting in a sitting position, according to the WHO/Inter-
national Society of Hypertension Recommendation, then their
mean was taken and the mean arterial pressure was calcu-
lated.24 Hypertension (Ht) was deﬁned as systolic
BP(SBP) > 140 mmHg, diastolic BP (DBP) > 90 mmHg, or
they were on maintenance use of antihypertensive therapy.
Determination of body mass index (BMI) was also calculated.25
Following eight hours fasting period, ﬁve ml venous blood
were withdrawn from all subjects. For patients, this was done
immediately before midweek dialysis session. Two ml was dis-
pended into K3EDTA vacutainer and mixed gently for the
genomic analysis. The rest were dispended into plain vacutain-
er and the obtained serum was used for estimation of glucose
and creatinine levels as well as the alanine aminotransferase
activity using Humaster 300 clinical chemistry analyzer
(Human GmbH, Germany).
Detection of AT1RA1166C gene polymorphism was done
as follows:
1. Genomic DNA extraction from the peripheral blood leuko-
cytes was done26, usingGene JETGenomic DNAPuriﬁca-
tion kit (Fermentas). Then the integrity of the extracted
DNAwas assessed by two ways: 2% agarose gel electropho-
resis27 and estimation of its concentration and purity28, using
Thermo Scientiﬁc Nano Drop 1000 spectrophotometer
(Thermo Fisher Scientiﬁc, Wilmington, Delaware, USA).
2. Detection of A1166C single nucleotide polymorphism
(SNP) of the AT1R gene was done by polymerase chain
reaction/restriction fragment length polymorphism
(PCR/RFLP) strategy18, where the 850 bp fragment was
generated by PCR ampliﬁcation using a forward primer
(50-AAT GCT TGT AGC CAA AGT CAC CT-30) and a
reverse primer (50-GGT TTT GCT TTG TCT TGT TG-
30) (Fermentas – Thermo, USA). The reaction mixture
was performed where 5 ll extracted DNA was mixed with
0.5 ll of each primer and 12.5 ll Dream Tag PCR Green
master mix (Fermentas-Thermo, USA) and completed to
ﬁnal volume of 25 ll with nuclease free sterile water. The
PCR ampliﬁcation of 5 ll genomic DNA was done on the
S-96 thermo cycler (Quanta Biotech, UK) as initial dena-
turation for one cycle at 94 C for 2 min, followed by 12
cycles ampliﬁcation (denaturation at 94 C for 1 min,
annealing ‘‘touchdown’’ at 72 C down to 60 C for 1 min
and extension at 72 C for 2 min), then 28 cycles ampliﬁca-
tion (denaturation at 94 C for 1 min, annealing at 60 C
for 1 min and extension at 72 C for 2 min). The ﬁnal exten-
sion was done by one cycle at 72 C for 10 min. Then 12 ll
of the PCR product was visualized by 2% agarose gel elec-
trophoresis stained by ethidium bromide as bands at
850 bp.
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uct, using 200 units (10 U/ll) Dde I enzyme (Promega,
USA) which targeted speciﬁc sequence of ampliﬁed DNA
product. It cuts the product into 2 pieces (600, 250 bp) long.
An additional Dde I recognition site is present in C type
variant to split the 250 bp into 110 and 140 bp fragments.
Visualization of the digestion products was done on 2%
agarose gel electrophoresis stained with ethidium bromide,
where the homozygote AA produced 2 bands (600 & 250 bp
long), the homozygote CC produced 3 bands (600, 140,
110 bp long) and the heterozygote AC produced all 4 bands
(600, 250, 140 & 110 bp long).
3.1. Statistical analysis29
It was done using SPSS program (version 20) (Chicago, USA).
D’Agostino–Pearson K-squared test for normality was done to
test for the deviation from the normal distribution. For nor-
mally distributed quantitative variables, mean ± S.D.,
unpaired t-test and Pearson’s correlation were used. While
median and range (min.–max.), Mann Whitney test and Spear-
man correlation were used for data that were abnormally dis-
tributed. For data of nominal variables (frequency or
percentage), the Chi–Square test (v2 test) with Monte Carlo
estimate of the exact p value and Fisher’s exact test were used.
Hardy–Weinberg Equilibrium30 was done to calculate the
equilibrium expected genotypic proportions. Odd’s ratio
(OR) with 95% conﬁdence intervals (CI) were estimated for
the effects of high risk alleles. Multiple linear regressionTable 2 Comparison of AT1R(A1166C) genotype among the studi
Observed frequency H.W. expected f
n. % n.
Controls (n = 100):
AA (wild) 76 76 77.44
AC (hetero) 24 24 21.12
CC (mutant) 0.0 0.0 1.44
HD patients (n = 102):
AA (wild) 67 65.7 65.1
AC (hetero) 29 28.4 32.8
CC (mutant) 6 5.9 4.1
Fisher exact P value 0.024
Table 1 Some clinical and laboratory data of the studied groups.
BMI (kg/m2) Glucose (mg/dl) Creatinin
Controls (n= 100): mean ±
S.D./min.–max & median
28.6±4.13 88.9±8.79 0.5–1.4
0.9
HD patient (n= 102): mean ±
S.D./min.–max. & median
16–39.5 57–377 3.4–16.8
24.0 99.0 9.7
PMW 0.000 0.000 0.000analysis was done to analyze the relationship between a
dependent variable (mean arterial blood pressure) and several
other anticipated independent predictor variables. A p value
of <0.05 was considered statistically signiﬁcant. The
generalization of Casagrande’s method proposed by Fleiss
was used to estimate the statistical power of our study.4. Results
The whole HD patients showed signiﬁcantly higher levels of
glucose, creatinine, total cholesterol, LDL-C and triglycerides
than their corresponding values in controls. In addition, they
showed signiﬁcantly lower levels of BMI and HDL-cholesterol
than their corresponding values in controls (Table 1).
The AT1R A 1166C genotyping in controls and whole HD
patients were in agreement with H.W. equilibrium (Table 2).
The HD patients showed decreased frequency of the wild
(AA) genotype and increased frequency of heterotype (AC)
and mutant (CC) type than the corresponding control values
(P= 0.024) (Table 2).
In whole HD patients, the frequency allele A showed signif-
icantly lower percentage and the frequency of C allele showed
signiﬁcantly higher percentage than their corresponding per-
centage in controls (pFE = 0.03) (Table 3).
On dividing the HD patients according to the presence of
hypertension, there were no signiﬁcant differences in either
the frequency of genotypes or in the allele frequency between
normotensive and hypertensive HD patients (PFE = 0.612 &
0.258) (Table 4).ed groups and their agreement with H.W. equilibrium.
requency Statistical analysis (observe. # H.W. expect
% v2 P
v2 = 1.86 P= 0.173 (N.S.)
77.44
21.12
1.44
v2 = 1.34 P= 0.246 (N.S.)
63.8
32.1
4.1
(mg/dl) ALT (U/L) Chol (mg/dl) HDL-C (mg/dl) LDL-C
(mg/dl)
TG
(mg/dl)
6–69 188.3± 30–80 121.0± 34–240
19.5 39.2 41 38.1 88.5
6–139 98–384 22–68 39–282 43–400
16 218.5 35 182 162
N.S. 0.05 0.001 0.001 0.000
Table 5 Comparison of AT1R(A1166C) genotype among hypertensive patients receiving different antihypertensive therapy.
Pts. Taking non RAS blockers (n= 38) Pts. Taking RAS blockers (n= 34) Fisher Exact with Freeman Halton
n. % n. % P value
AA 24 63.2 21 61.8 0.855 (N.S.)
AC 12 31.5 10 29.4
CC 2 5.3 3 8.8
Table 6 Comparison of AT1R SNP in relation to sex.
Controls (n= 100) HD patients (n= 102)
F (n= 65) M (n= 35) F (n= 52) M (n= 50)
AA 51(78.5%) 25(71.4) 31(59.6%) 36(72%)
AC 14(21.5%) 10(28.6%) 18(34.6%) 11(22%)
CC 0.0(0%) 0.0(0%) 3(5.8%) 3(6%)
PF.E.-value & Freeman Halton 0.111 (N.S.) 0.469 (N.S.)
Table 7 Comparison of AT1R SNP in relation to age.
Controls (n= 100) HD patients (n= 102)
650y (n= 30) >50y (n= 70) 650y (n= 52) >50y (n= 50)
AA 27(88.5%) 50(71.2%) 37(71.2%) 30(60%)
AC 3(11.1%) 20(28.8%) 12(23.0%) 17(34%)
CC 0.0(0%) 0.0(0%) 3(5.8%) 3(6%)
PF.E.-value & Freeman Halton 0.111 (N.S.) 0.469 (N.S.)
Table 3 Comparison of allele frequency among the studied groups.
Controls (n= 100) HD patients (n= 102) Statistical analysis
n. % n. % v2 PFE OR
A allele 176 88 163 80 4.91 0.03 OR= 1.84 95% C.I. = 1.07–3.19
C allele 24 12 41 20
Based on Fisher’s exact-test results, the relative risk approximated by an Odds ratio of (1.84) and our minor allele frequency of (0.12) the power
of our sample size to detect association was estimated to be (0.544).
Table 4 Comparison of AT1R(A1166C) genotype among normo-and hypertensive HD patients.
Normotensive HD pts. (n= 30)
(MAP 88 ± 9.8 mmHg)
Hypertensive HD pts.
(n= 72) (MAP 98 ± 13.7 mmHg)
Statistical analysis
n. % n. % v2 PFE OR
AA 22 73.4 45 62.5 0.612 (N.S.)
AC 7 23.3 22 30.6
CC 1 3.3 5 6.9
A allele 51 85 112 78 1.38 0.258 (N.S.) OR= 1.69 95% C.I. = 0.7–3.6
C allele 9 15 32 22
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the type of anti-hypertensive therapy given, no signiﬁcant dif-
ference in the AT1RA 1166C genotype was found between
those receiving RAS suppressors antagonists and those receiv-
ing other antihypertensive drugs (PFE = 0.866) (Table 5).No signiﬁcant difference in the frequency of AT1R geno-
type according to change in sex in either controls or HD
patients (Table 6). Also, no signiﬁcant changes in it between
those 650 years and those >50 years in either controls or
HD patients (Table 7).
Table 8 Final multiple regression analysis of MAP.
Beta T Signiﬁcance
Constant 13.743 0.000
LDL-C 0.204 2.178 0.032*
Duration of analysis 0.217 2.272 0.025*
BMI 0.294 3.065 0.003*
Age 0.162 1.704 0.092*
AT1R(A1166C) genotype 0.082 0.853 0.396 (N.S.)
* Signiﬁcant.
Angiotensin II type 1 receptor (A1166C) gene polymorphism 343The ﬁnal results of multiple linear regression analysis with
mean arterial blood pressure as the dependent variable
revealed that it is not dependent on AT1RA1166C genotype,
but they ended up with 4 independent variable (LDL-choles-
terol, duration of dialysis, age and BMI (Table 8).5. Discussion
The RAS genes have been investigated as potential etiologic
candidates for cardiovascular11,14 and renal diseases.4,5 Most
of the known effects of Ang II, the powerful effector peptide
of RAS, are mainly mediated by Ang II type 1 receptor
(At1R).
31
The AT1R is a member of G-protein coupled receptor
superfamily that is expressed in most tissues.14 Human AT1R
gene is located on chromosome 3q21–25. The AT1R activation
leads to vasoconstriction and water retention.32 It may also
regulate cell proliferation and vascular extra cellular protein
synthesis, with effects on renal vasculature and glomerular
ﬁborsis.4
It was reported that the c-allele of AT1RA1166C gene poly-
morphism may be associated with a faster decline in renal
functions.33 It has been suggested that the renal and systemic
Ang II activity would be augmented in subjects with c-allele
of AT1RA1166C gene polymorphism.
5
Conﬂicting results were reported about the relation between
the presence of AT1R C-1166 allele and kidney damage: Bur-
aczynska et al. in 200220 and in 200634 found an association
between this allele and the progression to ESRD. Others5
reported that the underlying diagnosis may modify the associ-
ation of genetic polymorphism and dialysis dependent ESRD.
On the other hand, Coll et al.21 in China and Lee et al.4 in
Spain found that the faster progression of renal damage was
associated with AA genotype.
In the present study, the genotype distribution of AT1-
RA1166C among controls and HD patients was in agreement
with Hardy–Weinberg equilibrium (P= 0.173, 0.246; respec-
tively) (Table 2). In addition, the HD patients showed signiﬁ-
cantly higher frequency of CC (5.9%) and signiﬁcantly lower
frequency of AA (65.7%) of AT1R genotype than the corre-
sponding values (0%, 76% respectively) in controls
(p= 0.024) (Table 2). Also, HD patients showed higher per-
centage (20%) of c-allele than that (12%) in controls
(P= 0.03) (Table 3). Similar results was reported by El-Sha-
maa et al.12 as they found signiﬁcantly higher frequency of
the c-allele and of homozygous CC genotype in Egyptian
HD children than those in controls. Also, the same ﬁndings
were shown in adult HD in 2002 by Buraczynska et al.20 Theyalso reported in 2006 an association between AT1R A/C
polymorphism and progression of renal disease.34 Therefore,
the c-allele appeared to be a possible predictor of fast
progression to ESRD.20
In the present study, no signiﬁcant differences in the AT1R
A1166C gene polymorphism in relation to either age or sex
(Tables 6 and 7). In addition, the multiple regression analysis
did not reveal any dependency of serum creatinine or duration
of dialysis on the presence of this polymorphism.
In the multiple linear regression analysis of El-Shamaa
et al.12, the c-allele and serum urea were variables that were
independently associated with systolic blood pressure (SBP).
So in hypertensive HD patients, the AC/CC genotype of
AT1R gene polymorphism could contribute in a synergistic
way to renal damage. Fabris et al.35 found an increase progres-
sion to renal disease among hypertensive patients with AT1R
A1166C gene polymorphism.
Studies concerning the association of this polymorphism
and hypertension in different ethnic patients yielded conﬂicting
results: some studies found an association.14–16,19,36,37 While
others did not show such association13,17,38–42, Others found
such association in only male subjects.43
In the present study, on dividing the HD patients according
to the presence of hypertension, there were no signiﬁcant dif-
ferences in either the AT1R A1166C genotyping or in the allele
frequency between normotensive and hypertensive HD
patients (Table 4).This non signiﬁcant difference may be due
to small sample sizes when dividing HD patients to normoten-
sive and hypertensive. Therefore, on pooling those with AC
and CC genotypes together, 37.5% of hypertensive versus
26.6% of normotensive HD patients had both AC and CC
genotypes. In addition, 22% of hypertensive versus 15% of
normotensive had c-allele (Table 4). However, also no signiﬁ-
cant difference was found.
It could be suggested that the discrepancies in the results of
the association of this polymorphism with hypertension may
be ethnic group-related and the possibility that this polymor-
phism predisposed to hypertension still to be proved.16,18,37,41
In addition, it could be due to the use of different methods
and techniques in determining this polymorphism, beside the
use of different (or even inappropriate) statistical methods
for analyzing the data. The presence of linkages disequilibrium
between AT1RA1166C gene and other polymorphism may be
another explanation.15,44
Whatever the role of AT1R polymorphism in developing
hypertension, regimen inhibiting AT1R expression resulted in
greater antihypertensive efﬁcacy and organ protection.45
Therefore, control of blood pressure (BP) is important to
improve the outcome of these patients.46
In the present study, no signiﬁcant differences were found
in AT1R A1166C genotyping between hypertensive HD
patients receiving angiotensin antagonists (RAS blockade)
and those receiving non-angiotensin antagonists (Table 5).
Also, the mean arterial pressure (MAP) showed no signiﬁcant
difference between the two subgroups. Absence of this differ-
ence may be due to the fact that most of hypertensive HD
patients took combined antihypertensive therapy to achieve
adequate BP control.47 Also, inter-individual variation in the
responses to therapy have been reported.12 It seems that
RAS blockade in these patients would provide signiﬁcant sur-
vival beneﬁts,48 however, no such effect was found in other
study.49
344 H. El-banawy et al.In the present study, the ﬁnal multiple regression analysis
revealed that when using mean arterial pressure (MAP) as
independent predictor, the LDL-chol, duration of dialysis,
BMI and age; but not the AT1RA1166C SNP were the only
four signiﬁcant dependent variables (Table 8).
In conclusion, as this study proved an association between
AT1RA1166 C gene polymorphism and ESRD progression, it
may be suggested that CC/AC genotype could serve as a pre-
dictor of an early ESRD and could, in the future, become an
important part of the clinical process of renal risk identiﬁca-
tion. However, this suggestion needs to be conﬁrmed in
another study on larger Egyptian patients. Also, the mecha-
nism(s) by which this polymorphism affects the progression
of ESRD remain to be elucidated.
The study did not prove the association of this polymor-
phism with hypertension. This may be due to the relatively
small number of subjects enrolled in the study.
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